Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma

This is a case of a 26-year-old male patient, with relapsing Hodgkin lymphoma, treated with nivolumab and brentuximab-vedotin, who was admitted with hyperglycemia and severe insulin resistance requiring approximately 2000 units of intravenous insulin per day. He had no prior diagnosis of diabetes. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tama, Elif, Black, Meghan, Moustafa, Muhamad Alhaj, Hurtado, Maria D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629972/
https://www.ncbi.nlm.nih.gov/pubmed/37942131
http://dx.doi.org/10.1210/jcemcr/luad121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629972/
https://www.ncbi.nlm.nih.gov/pubmed/37942131
http://dx.doi.org/10.1210/jcemcr/luad121

Ejemplares similares